Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy
Recommended Citation
Ho CL, Ettinger DS, Chen PN, Cheng H, Wen WC, Wu SY, Jahan TM, Fidler MJ, Lash BW, Rybkin II, and Stanton N. Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy. J Clin Oncol 2019; 37.
Document Type
Conference Proceeding
Publication Date
9-2019
Publication Title
J Clin Oncol
Abstract
Background: The aim of this study was to assess the efficacy of Antroquinonol in patients with stage IV NSCLC after failure in twolines of anti-cancer therapy. Methods: Patients with stage IV nonsquamous NSCLC who have failed at 2-4 lines of anti-cancer therapy were eligible, though early stage or naive patients may voluntarily participate. A maximum of 30 evaluable patients were to receive Antroquinonol 600mg per day, of which 15 patients were to be KRAS-positive and 15 patients KRAS negative. The primary endpoint of the study was progression-free survival from the start of treatment to week 12 with disease control rate and overall survival as key secondary endpoints. Results: There were 31 patients enrolled with évaluable population 30 patients, of which 15 patients were KRAS positive and 15 patients KRAS negative. 73% were with at least two prior chemotherapy. The median PFS of 7 patients with 2 prior chemotherapy was 22.9 weeks (95% confidence interval [CI]: 5.0, 31.1); and 11 patients with more than 2 prior chemotherapy was 11.9 weeks (95% confidence interval [CI]: 6.0, 14.1), with a 1 -year PFS of 11.4%. Of 11 patients who had had more than 2 prior chemotherapy, the median OS was 47.3 weeks (95% CI: 14.1,-), with a 1-year OS of 39.3%, and the overall disease control rate was 72.7%, with 100% in KRAS negative and 50% in KRAS positive. No systemic toxicities were observed. Conclusions: The monotherapy of Antroquinonol brought up higher disease control rates and longer progression-free survival and overall survival, compared with historical data. Although KRAS negative shows much better than KRAS positive group, Antroquinonol still work well with KRAS positive patients.
Volume
2019
Issue
37
